Literature DB >> 9862373

Thymus-dependent monoclonal antibody-induced protection from transferred diabetes.

N M Parish1, L Bowie, S Zusman Harach, J M Phillips, A Cooke.   

Abstract

It is well established that long-term protection from insulin-dependent diabetes mellitus (IDDM) can be afforded to non-obese diabetic (NOD) mice by a short course of non-depleting (nd) anti-CD4 monoclonal antibodies (mAb). Since it is increasingly apparent that the CD8+ T cell plays a prominent role in the development of IDDM, we have investigated the effect of an anti-CD8 mAb (YTS 105) of the same isotype in both spontaneous and induced IDDM in NOD mice. Treatment with YTS 105 for 3 weeks was able to prevent the transfer of IDDM for a long period, and also substantially reduced spontaneous IDDM in female NOD mice. The role of the thymus in tolerance induction by these antibodies was studied. In the adult transfer model, thymectomized NOD mice, unlike their euthymic counterparts, were not protected long-term by treatment with YTS 105, and began to become overtly diabetic shortly after treatment. This was also true when the nd anti-CD4 mAb was used. Protection from spontaneous disease was not affected in the same way by thymectomy. The reasons for the observed effect of the thymus in the transfer model, and the differences between the two models that may explain the contrasting results are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862373     DOI: 10.1002/(SICI)1521-4141(199812)28:12<4362::AID-IMMU4362>3.0.CO;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial.

Authors:  J Ludvigsson; U Samuelsson; J Ernerudh; C Johansson; L Stenhammar; G Berlin
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.

Authors:  Aaron J Martin; Matthew Clark; Gregory Gojanovich; Fatima Manzoor; Keith Miller; Douglas E Kline; Y Maurice Morillon; Bo Wang; Roland Tisch
Journal:  JCI Insight       Date:  2016-10-20

3.  The crystal structure of CD8 in complex with YTS156.7.7 Fab and interaction with other CD8 antibodies define the binding mode of CD8 alphabeta to MHC class I.

Authors:  D A Shore; H Issafras; E Landais; L Teyton; I A Wilson
Journal:  J Mol Biol       Date:  2008-10-07       Impact factor: 5.469

4.  Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations.

Authors:  Jenny M Phillips; Nicole M Parish; Tim Raine; Chris Bland; Yvonne Sawyer; Hugo De La Peña; Anne Cooke
Journal:  Rev Diabet Stud       Date:  2009-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.